Two Sigma Advisers
SKYE icon

Two Sigma Advisers’s Skye Bioscience SKYE Stock Holding History

Two Sigma Advisers’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-40,982
Closed -$30.7K – 2241
2025
Q4 		$30.7K Buy
+40,982
New +$59.9K ﹤0.01% 2298
2025
Q1 		– Sell
-11,200
Closed -$31.7K – 2611
2024
Q4 		$31.7K Buy
+11,200
New +$46.8K ﹤0.01% 2314

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Two Sigma Advisers's SKYE Position: Q1 2026 in Review

Two Sigma Advisers sold out of Skye Bioscience (SKYE) in Q1 2026, closing a stake of 40,982 shares — an estimated $30.7K sold.

Two Sigma Advisers first reported a position in SKYE in Q4 2024 and held it in 2 quarters. The position peaked at $31.7K in Q4 2024. 39 funds tracked by Wall St. Rank hold SKYE as of Q1 2026.

  • Two Sigma Advisers reported no remaining Skye Bioscience position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 40,982 Skye Bioscience shares in Q1 2026, an estimated $30.7K.
  • Two Sigma Advisers first reported a position in Skye Bioscience in Q4 2024 and held it in 2 quarters.
  • Two Sigma Advisers's Skye Bioscience position peaked at $31.7K in Q4 2024.
  • 39 funds tracked by Wall St. Rank held Skye Bioscience as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.